| Dr Anthony F Afong, MD | |
|
150 Sw Chamber Court, Suite 105, Port St Lucie, FL 34986-3413 | |
| (772) 807-9000 | |
| (772) 807-9087 |
| Full Name | Dr Anthony F Afong |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 28 Years |
| Location | 150 Sw Chamber Court, Port St Lucie, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801864160 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Options Home Health | West palm beach, FL | Home health agency |
| Cleveland Clinic Martin North Hospital | Stuart, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Florida Pain And Rehabilitation Associates Inc | 6204732605 | 60 |
News Archive
In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.
An international research group with members from the University of Basel, several EU countries, Israel and the USA, analyzed patient satisfaction with pain treatment after surgery.
Imagine millions of cancer cells organized in thousands of small divots. Hit these cells with drugs and when some cells die, you have a candidate for a cancer drug. But a review published this week in the journal Expert Opinion on Drug Discovery argues that these 2D models in fact offer very little information about a potential drug's effects in the body and may often give researchers misleading results.
An international team of investigators from centers in the United States and the United Kingdom, including Weill Cornell Medical College, have been awarded a grant for $10 million over a three-year period to study the molecular underpinnings of metastatic prostate cancer while creating a comprehensive testing system to optimize personalized treatments.
› Verified 6 days ago
| Entity Name | Florida Pain And Rehabilitation Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053363457 PECOS PAC ID: 6204732605 Enrollment ID: O20031219000145 |
News Archive
In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.
An international research group with members from the University of Basel, several EU countries, Israel and the USA, analyzed patient satisfaction with pain treatment after surgery.
Imagine millions of cancer cells organized in thousands of small divots. Hit these cells with drugs and when some cells die, you have a candidate for a cancer drug. But a review published this week in the journal Expert Opinion on Drug Discovery argues that these 2D models in fact offer very little information about a potential drug's effects in the body and may often give researchers misleading results.
An international team of investigators from centers in the United States and the United Kingdom, including Weill Cornell Medical College, have been awarded a grant for $10 million over a three-year period to study the molecular underpinnings of metastatic prostate cancer while creating a comprehensive testing system to optimize personalized treatments.
› Verified 6 days ago
| Entity Name | National Surgical Centers Of America Llc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1770724122 PECOS PAC ID: 0143365205 Enrollment ID: O20100301000970 |
News Archive
In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.
An international research group with members from the University of Basel, several EU countries, Israel and the USA, analyzed patient satisfaction with pain treatment after surgery.
Imagine millions of cancer cells organized in thousands of small divots. Hit these cells with drugs and when some cells die, you have a candidate for a cancer drug. But a review published this week in the journal Expert Opinion on Drug Discovery argues that these 2D models in fact offer very little information about a potential drug's effects in the body and may often give researchers misleading results.
An international team of investigators from centers in the United States and the United Kingdom, including Weill Cornell Medical College, have been awarded a grant for $10 million over a three-year period to study the molecular underpinnings of metastatic prostate cancer while creating a comprehensive testing system to optimize personalized treatments.
› Verified 6 days ago
| Entity Name | National Surgical Centers Of America Llc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1063853174 PECOS PAC ID: 0143365205 Enrollment ID: O20131219001320 |
News Archive
In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.
An international research group with members from the University of Basel, several EU countries, Israel and the USA, analyzed patient satisfaction with pain treatment after surgery.
Imagine millions of cancer cells organized in thousands of small divots. Hit these cells with drugs and when some cells die, you have a candidate for a cancer drug. But a review published this week in the journal Expert Opinion on Drug Discovery argues that these 2D models in fact offer very little information about a potential drug's effects in the body and may often give researchers misleading results.
An international team of investigators from centers in the United States and the United Kingdom, including Weill Cornell Medical College, have been awarded a grant for $10 million over a three-year period to study the molecular underpinnings of metastatic prostate cancer while creating a comprehensive testing system to optimize personalized treatments.
› Verified 6 days ago
| Entity Name | National Surgical Centers Of America Llc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1992040976 PECOS PAC ID: 0143365205 Enrollment ID: O20140424001550 |
News Archive
In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.
An international research group with members from the University of Basel, several EU countries, Israel and the USA, analyzed patient satisfaction with pain treatment after surgery.
Imagine millions of cancer cells organized in thousands of small divots. Hit these cells with drugs and when some cells die, you have a candidate for a cancer drug. But a review published this week in the journal Expert Opinion on Drug Discovery argues that these 2D models in fact offer very little information about a potential drug's effects in the body and may often give researchers misleading results.
An international team of investigators from centers in the United States and the United Kingdom, including Weill Cornell Medical College, have been awarded a grant for $10 million over a three-year period to study the molecular underpinnings of metastatic prostate cancer while creating a comprehensive testing system to optimize personalized treatments.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anthony F Afong, MD 11350 Mccormick Rd., Executive Plaza 1, Suite 501, Hunt Valley, MD 21031 Ph: (678) 841-7135 | Dr Anthony F Afong, MD 150 Sw Chamber Court, Suite 105, Port St Lucie, FL 34986-3413 Ph: (772) 807-9000 |
News Archive
In what is believed to be the most comprehensive molecular characterization to date of the most common - and often treatment-resistant - form of kidney cancer, researchers at Johns Hopkins' departments of pathology and oncology, Johns Hopkins Kimmel Cancer Center, and the Johns Hopkins University School of Medicine report evidence for at least three distinct subtypes of clear cell renal cell carcinoma (ccRCC), along with new revelations about the proteins that define them.
An international research group with members from the University of Basel, several EU countries, Israel and the USA, analyzed patient satisfaction with pain treatment after surgery.
Imagine millions of cancer cells organized in thousands of small divots. Hit these cells with drugs and when some cells die, you have a candidate for a cancer drug. But a review published this week in the journal Expert Opinion on Drug Discovery argues that these 2D models in fact offer very little information about a potential drug's effects in the body and may often give researchers misleading results.
An international team of investigators from centers in the United States and the United Kingdom, including Weill Cornell Medical College, have been awarded a grant for $10 million over a three-year period to study the molecular underpinnings of metastatic prostate cancer while creating a comprehensive testing system to optimize personalized treatments.
› Verified 6 days ago
Grady Ernst, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2542 Se Welsh St, Port St Lucie, FL 34984 Phone: 484-571-4111 | |
Dr. Annalyssa Laney, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1655 Se Walton Rd, Port St Lucie, FL 34952 Phone: 772-337-1333 | |
Mrs. Karrie L Chapman, PT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 9401 Sw Discovery Way Ste 202, Port St Lucie, FL 34987 Phone: 772-288-2400 Fax: 772-419-0143 | |
Patrick M. Gonzalez, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1420 Sw Saint Lucie West Blvd, Suite 102, Port St Lucie, FL 34986 Phone: 772-873-1005 Fax: 772-873-9106 | |
Matthew Wolfe, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1400 Se Goldtree Dr Ste 205, Port St Lucie, FL 34952 Phone: 772-335-7966 Fax: 772-335-7963 | |
Dr. Jason Paul Williams, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 9077 S Federal Hwy, Port St Lucie, FL 34952 Phone: 772-335-4770 Fax: 772-335-4133 | |
Richard F Mcfague, M.D Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 1700 Se Hillmoor Dr, Port St Lucie, FL 34952 Phone: 561-427-7047 |